Ana Claudia de Souza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ana Claudia de Souza has a total of 255 co-authors. Here are the top co-authors by number of shared publications:
- Sheila Cristina Ouriques Martins
Neurology Department, Hospital Moinhos de Vento, Porto Alegre, Brazil
13 shared publications - Leonardo Augusto Carbonera
Hospital Moinhos de Vento
12 shared publications - Gisele Sampaio Silva
Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Neurologia e Neurocirurgia, São Paulo SP, Brazil
8 shared publications - Octávio Marques Pontes-Neto
Department of Neurology, Ribeirão Preto Medical School, University of São Paulo, Brazil
7 shared publications - Pablo Amaya
Fundación Valle del Lili
5 shared publications - Pedro Ordunez
Pan American Health Organization
5 shared publications
Latest Publications
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19) , e047114
Stroke Burden Attributable to Risk Factors in the Americas, 1990 to 2021: A Temporal Trends Analysis From the GBD Study 2021
Background: Stroke burden varies across the Americas, yet data on modifiable risk factor contributions remain limited. Methods: Using GBD (Global Burden of Disease) study 2021 data, we analyzed stroke mortality and disability‐adjusted life‐year (DALY) rates attributable to 23 modifiable risk factors across 39 countries and territories in the Americas. Age‐standardized rates were compared by sex, stroke subtype, region, and Socio‐Demographic Index; age‐specific estimates used 5‐year groups (25–95+ years). Trends were assessed using average annual percentage change (AAPC) from Joinpoint regression. Results: In 2021, 78.8% (95% uncertainty interval, 70.1%–85.9%) of stroke deaths and 76.9% (68.2%–83.6%) of DALYs were attributable to the 23 risk factors combined. High systolic blood pressure was the leading contributor, accounting for 20.87 attributable deaths (95% uncertainty interval, 15.17–25.80) and 453.30 DALYs (333.16–556.41) per 100 000, representing 54.8% of deaths and 52.2% of DALYs. From 1990 to 2021, the largest reductions occurred for household air pollution from solid fuels (deaths AAPC, −5.09% [95% CI, −5.17 to −5.02]; DALYs AAPC, −4.92% [−4.98 to −4.86]) and secondhand smoke (deaths AAPC, −3.45% [−3.49 to −3.41]). Reductions were minimal for high body mass index (deaths AAPC, −0.54% [−0.59 to −0.49]; DALYs AAPC, −0.42% [−0.46 to −0.37]), high fasting plasma glucose (deaths AAPC, −1.10% [−1.14 to −1.06]), and dietary risks; high body mass index burden increased in the Caribbean, notably in Haiti and the Dominican Republic. Stroke deaths attributable to high temperature increased >3.5% annually (AAPC) in Panama, Jamaica, and the Dominican Republic. High systolic blood pressure burden remained highly unequal, with age‐standardized death rates of 10.42 per 100 000 in high–Socio‐Demographic Index versus 109.33 in low–Socio‐Demographic Index countries. Conclusions: Stroke burden attributable to modifiable risk factors declined overall, but marked disparities persisted. High systolic blood pressure remained dominant, whereas stalled or increasing burden from obesity, metabolic, and dietary risks highlights the need for equity‐focused prevention across the Americas.
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19) , e047114
Stroke Burden Attributable to Risk Factors in the Americas, 1990 to 2021: A Temporal Trends Analysis From the GBD Study 2021
Background: Stroke burden varies across the Americas, yet data on modifiable risk factor contributions remain limited. Methods: Using GBD (Global Burden of Disease) study 2021 data, we analyzed stroke mortality and disability‐adjusted life‐year (DALY) rates attributable to 23 modifiable risk factors across 39 countries and territories in the Americas. Age‐standardized rates were compared by sex, stroke subtype, region, and Socio‐Demographic Index; age‐specific estimates used 5‐year groups (25–95+ years). Trends were assessed using average annual percentage change (AAPC) from Joinpoint regression. Results: In 2021, 78.8% (95% uncertainty interval, 70.1%–85.9%) of stroke deaths and 76.9% (68.2%–83.6%) of DALYs were attributable to the 23 risk factors combined. High systolic blood pressure was the leading contributor, accounting for 20.87 attributable deaths (95% uncertainty interval, 15.17–25.80) and 453.30 DALYs (333.16–556.41) per 100 000, representing 54.8% of deaths and 52.2% of DALYs. From 1990 to 2021, the largest reductions occurred for household air pollution from solid fuels (deaths AAPC, −5.09% [95% CI, −5.17 to −5.02]; DALYs AAPC, −4.92% [−4.98 to −4.86]) and secondhand smoke (deaths AAPC, −3.45% [−3.49 to −3.41]). Reductions were minimal for high body mass index (deaths AAPC, −0.54% [−0.59 to −0.49]; DALYs AAPC, −0.42% [−0.46 to −0.37]), high fasting plasma glucose (deaths AAPC, −1.10% [−1.14 to −1.06]), and dietary risks; high body mass index burden increased in the Caribbean, notably in Haiti and the Dominican Republic. Stroke deaths attributable to high temperature increased >3.5% annually (AAPC) in Panama, Jamaica, and the Dominican Republic. High systolic blood pressure burden remained highly unequal, with age‐standardized death rates of 10.42 per 100 000 in high–Socio‐Demographic Index versus 109.33 in low–Socio‐Demographic Index countries. Conclusions: Stroke burden attributable to modifiable risk factors declined overall, but marked disparities persisted. High systolic blood pressure remained dominant, whereas stalled or increasing burden from obesity, metabolic, and dietary risks highlights the need for equity‐focused prevention across the Americas.
- Open Access
- 16 September 2026
- Published by S. Karger AG in Cerebrovascular Diseases
- p. 1
Women in Stroke: A Conversation with Dr. Aleksandra Pikula on Prevention, Women’s Health, Mentorship, and Leadership?
- 16 September 2026
- Published by S. Karger AG in Cerebrovascular Diseases
- p. 1
Open AccessWomen in Stroke: A Conversation with Dr. Aleksandra Pikula on Prevention, Women’s Health, Mentorship, and Leadership?
- 17 July 2026
- Published by SAGE Publications in International Journal of Stroke
Randomization of endovascular treatment with stent-retriever and/or thromboaspiration versus best medical therapy in acute ischemic stroke due to large vessel occlusion in the extended time window trial (RESILIENT-Extend): Rationale and design
Background: Randomized trials have demonstrated substantial benefit of mechanical thrombectomy (MT) in selected patients treated 6–24 h after stroke onset. However, these trials relied on advanced imaging not typically available in resource-constrained settings. The RESILIENT-Extend trial aims to evaluate the efficacy and safety of MT in the 8- to 24-h window using a pragmatic imaging selection based on non-contrast computed tomography (CT) and CT angiography alone. Methods: RESILIENT-Extend is a multicenter, randomized, controlled, open-label, blinded-endpoint, phase 3 trial conducted in Brazil. The planned sample size is 376 participants. Patients presenting with anterior-circulation large vessel occlusion within 8–24 h from time last known well will be randomized 1:1 to receive either MT plus best medical management (BMM) or BMM alone. The trial uses a minimization algorithm to balance prognostic variables including age, National Institutes of Health Stroke Scale (NIHSS), Alberta Stroke Program Early CT Score (ASPECTS), occlusion site, time window, and clinical site. The primary outcome is the distribution of 90-day modified Rankin Scale scores assessed by blinded central adjudication. Discussion: RESILIENT-Extend is one of the first randomized trials to evaluate MT in the extended window using a pragmatic selection strategy based exclusively on widely available imaging modalities (non-contrast CT and CT angiography), with a focus on scalability in real-world and resource-constrained settings. Trial Registration: clinicaltrials.govNCT04256096
- 17 July 2026
- Published by SAGE Publications in International Journal of Stroke
Randomization of endovascular treatment with stent-retriever and/or thromboaspiration versus best medical therapy in acute ischemic stroke due to large vessel occlusion in the extended time window trial (RESILIENT-Extend): Rationale and design
Background: Randomized trials have demonstrated substantial benefit of mechanical thrombectomy (MT) in selected patients treated 6–24 h after stroke onset. However, these trials relied on advanced imaging not typically available in resource-constrained settings. The RESILIENT-Extend trial aims to evaluate the efficacy and safety of MT in the 8- to 24-h window using a pragmatic imaging selection based on non-contrast computed tomography (CT) and CT angiography alone. Methods: RESILIENT-Extend is a multicenter, randomized, controlled, open-label, blinded-endpoint, phase 3 trial conducted in Brazil. The planned sample size is 376 participants. Patients presenting with anterior-circulation large vessel occlusion within 8–24 h from time last known well will be randomized 1:1 to receive either MT plus best medical management (BMM) or BMM alone. The trial uses a minimization algorithm to balance prognostic variables including age, National Institutes of Health Stroke Scale (NIHSS), Alberta Stroke Program Early CT Score (ASPECTS), occlusion site, time window, and clinical site. The primary outcome is the distribution of 90-day modified Rankin Scale scores assessed by blinded central adjudication. Discussion: RESILIENT-Extend is one of the first randomized trials to evaluate MT in the extended window using a pragmatic selection strategy based exclusively on widely available imaging modalities (non-contrast CT and CT angiography), with a focus on scalability in real-world and resource-constrained settings. Trial Registration: clinicaltrials.govNCT04256096
- 1 June 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (6) , 1796-1809
Integrating Digital Health Into Stroke Policies
Stroke remains a leading cause of death and disability worldwide. In response, many governments have developed stroke policies emphasizing prevention, early detection, timely treatment, and rehabilitation. However, the implementation of those strategies remains uneven, challenged by fragmented health systems, unequal access to care, and resource constraints. Digital health tools provide robust solutions to enhance national and regional stroke policies by improving data collection, care access and coordination, monitoring, education, and public engagement. This review explores how digital health can strengthen stroke care systems across different contexts, highlighting real-world applications, policy integration, and strategic enablers for equitable implementation.
- 1 June 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (6) , 1796-1809
Integrating Digital Health Into Stroke Policies
Stroke remains a leading cause of death and disability worldwide. In response, many governments have developed stroke policies emphasizing prevention, early detection, timely treatment, and rehabilitation. However, the implementation of those strategies remains uneven, challenged by fragmented health systems, unequal access to care, and resource constraints. Digital health tools provide robust solutions to enhance national and regional stroke policies by improving data collection, care access and coordination, monitoring, education, and public engagement. This review explores how digital health can strengthen stroke care systems across different contexts, highlighting real-world applications, policy integration, and strategic enablers for equitable implementation.
- 1 June 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (6) , 1810-1820
Midlife as the Critical Window for Women’s Stroke and Dementia Prevention: Pivotal Advances and Implementation Priorities
Women face a higher lifetime risk of stroke and dementia than men, yet prevention strategies are not optimally implemented for women. Midlife (ages 40–65) represents a critical yet underused life stage window for prevention. This period encompasses the menopausal transition, when hormonal, metabolic, vascular, and neurological changes converge. Despite this, women remain underrepresented in stroke trials, and sex-specific risk factors are poorly integrated into routine prevention. This review synthesizes the transformative advances in midlife women’s stroke and vascular dementia prevention from 2015 to 2025, drawing on evidence from clinical guidelines, cohort studies, neuroimaging studies, randomized trials, and implementation research. It highlights research priorities and an implementation framework for the future. Six major advances were identified: first, the 2024 American Heart Association/American Stroke Association guidelines introduced a class I recommendation to screen for adverse pregnancy outcomes. Second, neuroimaging now demonstrates that adverse pregnancy outcomes are linked to vascular brain injury decades after they occur. Third, the 2020 American Heart Association statement established menopausal transition as a distinct cardiometabolic and neurobiological transition affecting vascular brain health. Fourth, menopause hormone therapy controversies have resolved through evidence supporting personalized, timing-based approaches. Fifth, inflammatory and lipid biomarkers measured in midlife can predict stroke risk years out. Sixth, postmenopausal women show greater vascular benefits from physical activity. Despite these advances, women do not routinely receive appropriate screening or prevention recommendations. These findings support a comprehensive midlife assessment that incorporates reproductive history, menopausal transition status, and novel biomarkers alongside traditional risk factors, and should be offered streamlined recommendations for lifestyle strategies and menopause hormone therapy when indicated. Closing the implementation gap will require health system adaptation, provider education, and embedded pragmatic trials to incorporate these advances into routine care.
- 1 June 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (6) , 1810-1820
Midlife as the Critical Window for Women’s Stroke and Dementia Prevention: Pivotal Advances and Implementation Priorities
Women face a higher lifetime risk of stroke and dementia than men, yet prevention strategies are not optimally implemented for women. Midlife (ages 40–65) represents a critical yet underused life stage window for prevention. This period encompasses the menopausal transition, when hormonal, metabolic, vascular, and neurological changes converge. Despite this, women remain underrepresented in stroke trials, and sex-specific risk factors are poorly integrated into routine prevention. This review synthesizes the transformative advances in midlife women’s stroke and vascular dementia prevention from 2015 to 2025, drawing on evidence from clinical guidelines, cohort studies, neuroimaging studies, randomized trials, and implementation research. It highlights research priorities and an implementation framework for the future. Six major advances were identified: first, the 2024 American Heart Association/American Stroke Association guidelines introduced a class I recommendation to screen for adverse pregnancy outcomes. Second, neuroimaging now demonstrates that adverse pregnancy outcomes are linked to vascular brain injury decades after they occur. Third, the 2020 American Heart Association statement established menopausal transition as a distinct cardiometabolic and neurobiological transition affecting vascular brain health. Fourth, menopause hormone therapy controversies have resolved through evidence supporting personalized, timing-based approaches. Fifth, inflammatory and lipid biomarkers measured in midlife can predict stroke risk years out. Sixth, postmenopausal women show greater vascular benefits from physical activity. Despite these advances, women do not routinely receive appropriate screening or prevention recommendations. These findings support a comprehensive midlife assessment that incorporates reproductive history, menopausal transition status, and novel biomarkers alongside traditional risk factors, and should be offered streamlined recommendations for lifestyle strategies and menopause hormone therapy when indicated. Closing the implementation gap will require health system adaptation, provider education, and embedded pragmatic trials to incorporate these advances into routine care.
- Open Access
- 23 May 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 58, 101468
Implementation of stroke prevention: a review of challenges and opportunities in the Americas
- 23 May 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 58, 101468
Open AccessImplementation of stroke prevention: a review of challenges and opportunities in the Americas
- Top Cited PapersOpen Access
- 9 May 2026
- Published by Elsevier in The Lancet Primary Care
- Vol. 2 (5)
HEARTS 2.0: an implementation-oriented clinical pathway for integrated care of hypertension and cardiovascular–kidney–metabolic conditions in primary health care in the Americas
- 9 May 2026
- Published by Elsevier in The Lancet Primary Care
- Vol. 2 (5)
Top Cited PapersOpen AccessHEARTS 2.0: an implementation-oriented clinical pathway for integrated care of hypertension and cardiovascular–kidney–metabolic conditions in primary health care in the Americas
- Top Cited PapersOpen Access
- 22 April 2026
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 39 (8) , 956-965
Evidence-informed prioritization of interventions for integrating hypertension management into cardiovascular-kidney-metabolic care in primary health care: HEARTS 2.0 Phase 3
Background: HEARTS in the Americas is the regional adaptation of the WHO Global HEARTS Initiative. This paper presents Phase 3 of HEARTS 2.0, an evidence-informed process to prioritize clinical and health-system interventions to support the operationalization of integrated cardiovascular, kidney, and metabolic (CKM) care in primary health care (PHC) and to inform the update of the HEARTS Clinical Pathway. CKM conditions frequently coexist, sharing common risk factors and pathophysiological mechanisms that exacerbate cardiovascular disease burden. Despite their overlap, clinical practice often remains siloed due to condition-specific guidelines, and its integration remains limited. To prioritize evidence-informed clinical and health-system interventions that support the operationalization of integrated CKM care within PHC and inform the update of the HEARTS Clinical Pathway. Methods: Building on previous phases of HEARTS 2.0, a multidisciplinary panel evaluated 45 candidate interventions in different areas. The selection process utilized structured evidence appraisal, Evidence-to-Decision frameworks, and a modified RAND/UCLA appropriateness method involving anonymized rating rounds. Results: A total of 38 interventions were prioritized for implementation. Although hypertension management remains the primary entry point, the resulting framework integrates early detection of diabetes and chronic kidney disease, lifestyle interventions, risk-based combination pharmacotherapy, task-sharing, and longitudinal follow-up. Conclusions: By translating dispersed guideline recommendations into implementable interventions, Phase 3 of HEARTS 2.0 provides an evidence-informed basis for advancing integrated CKM care at scale in PHC and guiding the forthcoming update of the HEARTS Clinical Pathway. The resulting framework offers a flexible, scalable approach for countries confronting similar epidemiological and health system challenges.
- 22 April 2026
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 39 (8) , 956-965
Top Cited PapersOpen AccessEvidence-informed prioritization of interventions for integrating hypertension management into cardiovascular-kidney-metabolic care in primary health care: HEARTS 2.0 Phase 3
Background: HEARTS in the Americas is the regional adaptation of the WHO Global HEARTS Initiative. This paper presents Phase 3 of HEARTS 2.0, an evidence-informed process to prioritize clinical and health-system interventions to support the operationalization of integrated cardiovascular, kidney, and metabolic (CKM) care in primary health care (PHC) and to inform the update of the HEARTS Clinical Pathway. CKM conditions frequently coexist, sharing common risk factors and pathophysiological mechanisms that exacerbate cardiovascular disease burden. Despite their overlap, clinical practice often remains siloed due to condition-specific guidelines, and its integration remains limited. To prioritize evidence-informed clinical and health-system interventions that support the operationalization of integrated CKM care within PHC and inform the update of the HEARTS Clinical Pathway. Methods: Building on previous phases of HEARTS 2.0, a multidisciplinary panel evaluated 45 candidate interventions in different areas. The selection process utilized structured evidence appraisal, Evidence-to-Decision frameworks, and a modified RAND/UCLA appropriateness method involving anonymized rating rounds. Results: A total of 38 interventions were prioritized for implementation. Although hypertension management remains the primary entry point, the resulting framework integrates early detection of diabetes and chronic kidney disease, lifestyle interventions, risk-based combination pharmacotherapy, task-sharing, and longitudinal follow-up. Conclusions: By translating dispersed guideline recommendations into implementable interventions, Phase 3 of HEARTS 2.0 provides an evidence-informed basis for advancing integrated CKM care at scale in PHC and guiding the forthcoming update of the HEARTS Clinical Pathway. The resulting framework offers a flexible, scalable approach for countries confronting similar epidemiological and health system challenges.
- 26 September 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (4) , 438-446
The World Stroke Organization future leaders program: Building leadership capacity in global stroke care
Background: Leadership development is essential to advancing stroke care globally. The World Stroke Organization (WSO) Future Stroke Leaders Program (FSLP) was established to identify and support global early-career professionals in stroke care worldwide. The program offers structured leadership training, mentorship, and seed funding for implementation projects. Selection criteria prioritize diversity, leadership potential, and institutional support. The article describes the design and implementation of the WSO FSLP and evaluates its contribution to stroke care advancement, professional development, and global collaboration. Methods: This is a descriptive narrative of the WSO FSLP, based on program documentation, participant surveys, and public databases. Programmatic key performance indicators (KPIs) aligned with WSO’s strategic goals were used to track impact. Results: Among 56 participants in the first two cohorts, selected from over 35 countries, engagement with the WSO FSLP contributed to improved access to and delivery of care by developing stroke services in underserved areas, enhancing publication output, and supporting active involvement in international policy and advocacy efforts. Participants reported career advancement, increased research engagement, and expanded collaborative networks as a direct result of their participation in the program. Conclusions: The WSO FSLP is a model for developing global stroke leadership. Its impact spans clinical innovation, academic research, and policy influence, guiding implementation. Continued program adaptation to the changing international landscape, alumni engagement, and long-term impact evaluation will help sustain and scale worldwide contributions to stroke care equity.
- 26 September 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (4) , 438-446
The World Stroke Organization future leaders program: Building leadership capacity in global stroke care
Background: Leadership development is essential to advancing stroke care globally. The World Stroke Organization (WSO) Future Stroke Leaders Program (FSLP) was established to identify and support global early-career professionals in stroke care worldwide. The program offers structured leadership training, mentorship, and seed funding for implementation projects. Selection criteria prioritize diversity, leadership potential, and institutional support. The article describes the design and implementation of the WSO FSLP and evaluates its contribution to stroke care advancement, professional development, and global collaboration. Methods: This is a descriptive narrative of the WSO FSLP, based on program documentation, participant surveys, and public databases. Programmatic key performance indicators (KPIs) aligned with WSO’s strategic goals were used to track impact. Results: Among 56 participants in the first two cohorts, selected from over 35 countries, engagement with the WSO FSLP contributed to improved access to and delivery of care by developing stroke services in underserved areas, enhancing publication output, and supporting active involvement in international policy and advocacy efforts. Participants reported career advancement, increased research engagement, and expanded collaborative networks as a direct result of their participation in the program. Conclusions: The WSO FSLP is a model for developing global stroke leadership. Its impact spans clinical innovation, academic research, and policy influence, guiding implementation. Continued program adaptation to the changing international landscape, alumni engagement, and long-term impact evaluation will help sustain and scale worldwide contributions to stroke care equity.
- 14 August 2025
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 55 (4) , 518-525
Empowering Healthcare Professionals: Preventing Non-Communicable Vascular Diseases in the Transgender Community
Background: The health disparities faced by transgender and gender-diverse (TGD) individuals in accessing healthcare, particularly in the context of non-communicable diseases (NCDs) and cerebrovascular diseases, are a significant public health concern. Summary: This article highlights the importance of the early identification of NCDs and cerebrovascular diseases in TGD populations, emphasizing the need for culturally competent care and comprehensive healthcare strategies. Gender-affirming hormone therapy plays a crucial role in the health of transgender individuals. Yet, it is associated with increased cardiovascular risk, particularly among transgender females undergoing estrogen therapy. Studies show a higher prevalence of hypertension, hypercholesterolemia, prediabetes, and smoking in the TGD population, reinforcing the need for regular cardiovascular monitoring and targeted preventive strategies. Early identification of NCDs and cerebrovascular disease signs and symptoms is essential in mitigating long-term health complications and improving patient outcomes. Proactive screening and timely interventions can enhance quality of life, reduce healthcare disparities, and contribute to more cost-effective care strategies. Strengthening the integration of diagnostic tools and promoting inclusive healthcare policies will foster greater trust and engagement between transgender individuals and healthcare providers. Key Messages: Overall, this article underscores the need for inclusive healthcare policies and practices that address the unique healthcare needs of TGD individuals, improve health outcomes, and reduce disparities within this vulnerable population.
- 14 August 2025
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 55 (4) , 518-525
Empowering Healthcare Professionals: Preventing Non-Communicable Vascular Diseases in the Transgender Community
Background: The health disparities faced by transgender and gender-diverse (TGD) individuals in accessing healthcare, particularly in the context of non-communicable diseases (NCDs) and cerebrovascular diseases, are a significant public health concern. Summary: This article highlights the importance of the early identification of NCDs and cerebrovascular diseases in TGD populations, emphasizing the need for culturally competent care and comprehensive healthcare strategies. Gender-affirming hormone therapy plays a crucial role in the health of transgender individuals. Yet, it is associated with increased cardiovascular risk, particularly among transgender females undergoing estrogen therapy. Studies show a higher prevalence of hypertension, hypercholesterolemia, prediabetes, and smoking in the TGD population, reinforcing the need for regular cardiovascular monitoring and targeted preventive strategies. Early identification of NCDs and cerebrovascular disease signs and symptoms is essential in mitigating long-term health complications and improving patient outcomes. Proactive screening and timely interventions can enhance quality of life, reduce healthcare disparities, and contribute to more cost-effective care strategies. Strengthening the integration of diagnostic tools and promoting inclusive healthcare policies will foster greater trust and engagement between transgender individuals and healthcare providers. Key Messages: Overall, this article underscores the need for inclusive healthcare policies and practices that address the unique healthcare needs of TGD individuals, improve health outcomes, and reduce disparities within this vulnerable population.